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Identification of Differential Roles of MicroRNA-33a and -33b During
Atherosclerosis Progression With Genetically Modified Mice
Satoshi Koyama, MD, PhD; Takahiro Horie, MD, PhD; Tomohiro Nishino, MD, PhD; Osamu Baba, MD, PhD; Naoya Sowa, AD;
Yui Miyasaka, MS; Yasuhide Kuwabara, MD, PhD; Tetsushi Nakao, MD, PhD; Masataka Nishiga, MD, PhD; Hitoo Nishi, MD, PhD;
Yasuhiro Nakashima, MD, PhD; Fumiko Nakazeki, MD, PhD; Yuya Ide, MD; Masahiro Kimura, MD; Shuhei Tsuji, MD;
Randolph Ruiz Rodriguez, MD; Sijia Xu, MD; Tomohiro Yamasaki, MD; Chiharu Otani, MD; Toshimitsu Watanabe, MD;
Tomoyuki Nakamura, MD, PhD; Koji Hasegawa, MD, PhD; Takeshi Kimura, MD, PhD; Koh Ono, MD, PhD
Background-—MicroRNA (miR)-33 targets cholesterol transporter ATP-binding cassette protein A1 and other antiatherogenic
targets and contributes to atherogenic progression. Its inhibition or deletion is known to result in the amelioration of
atherosclerosis in mice. However, mice lack the other member of the miR-33 family, miR-33b, which exists in humans and other
large mammals. Thus, precise evaluation and comparison of the responsibilities of these 2 miRs during the progression of
atherosclerosis has not been reported, although they are essential.
Methods and Results-—In this study, we performed a comprehensive analysis of the difference between the function of miR-33a
and miR-33b using genetically modified mice. We generated 4 strains with or without miR-33a and miR-33b. Comparison between
mice with only miR-33a (wild-type mice) and mice with only miR-33b (miR-33a//miR-33b+/+) revealed the dominant expression
of miR-33b in the liver. To evaluate the whole body atherogenic potency of miR-33a and miR-33b, we developed apolipoprotein
E–deficient/miR-33a+/+/miR-33b/ mice and apolipoprotein E–deficient/miR-33a//miR-33b+/+ mice. With a high-fat and
high-cholesterol diet, the apolipoprotein E–deficient/miR-33a//miR-33b+/+ mice developed increased atherosclerotic plaque
versus apolipoprotein E–deficient/miR-33a+/+/miR-33b/ mice, in line with the predominant expression of miR-33b in the liver
and worsened serum cholesterol profile. By contrast, a bone marrow transplantation study showed no significant difference, which
was consistent with the relevant expression levels of miR-33a and miR-33b in bone marrow cells.
Conclusions-—The miR-33 family exhibits differences in distribution and regulation and particularly in the progression of
atherosclerosis; miR-33b would be more potent than miR-33a. ( J Am Heart Assoc. 2019;8:e012609. DOI: 10.1161/JAHA.119.
012609.)
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A therosclerotic disease is one of the leading causes ofdeath worldwide. Although many biological pathways are
involved in the pathogenesis of atherosclerosis, cholesterol
homeostasis plays an important role in disease progression.
Cholesterol-lowering therapy, especially using statins, is the
most common therapy to reduce the risk and progression of
atherosclerosis.1 However, numerous clinical studies indicate
the existence of “residual risks,” mainly consisting of
decreased high-density lipoprotein (HDL)-cholesterol2,3 and
increased triglyceride levels.4,5 HDL or HDL-cholesterol is the
most important component of cholesterol reverse transport,
which is the sole pathway in the human body for excreting
cholesterol from the body. The results of recent research
highlight the importance of not only the quantity but also the
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quality of HDL/HDL-cholesterol in atherosclerosis progres-
sion.6 Because HDL/HDL-cholesterol–modulating therapy is a
promising therapeutic approach for atherosclerotic disease,
rigorous research is required.
MicroRNAs (miRs) are a class of short, noncoding RNAs
that affect many biological pathways by repressing the
expression of coding genes both transcriptionally and post-
transcriptionally.7 Numerous miRs have been shown to be
involved in biological pathways and affect pathogenesis.
Notably, we and other groups have shown previously that miR-
33 potentially affects many biological pathways, including
cholesterol homeostasis.8–18 In vivo deletion or inhibition of
miR-33 using antisense oligonucleotide improved the serum
cholesterol profile and enhanced cholesterol reverse trans-
port of not only mice, but also nonhuman primates. These
favorable changes in serum cholesterol profile or cholesterol
reverse transport reduced atherosclerotic plaque progression
in mice.11,14 These observations suggest miR-33 as a
potential therapeutic target of atherosclerosis.
However, many challenges must be overcome before the
clinical application of anti–miR-33 therapy is realized. First,
we and other groups found that in vivo deletion of miR-33
results in obesity and impaired glucose tolerance in mice,17,18
which could be a potential adverse effect of anti–miR-33
therapy. Moreover, the human genome harbors miR-33b in
the intron 16 of sterol regulatory element-binding factor
(SREBF) 1, as a paralog of miR-33a (Figure 1A). These miR
sequences are almost the same, except at the 9th and 10th
nucleotide position immediately after the seed sequences
(Figure 1B). Notably, mouse, which is the most conventional
animal model of atherosclerosis, lacks miR-33b. Thus, the
target gene signature, spatiotemporal expression pattern, and
environmental regulation of miR-33b remain largely unknown.
Further investigation of the differences and similarities
between miR-33a and miR-33b in vivo is essential to confirm
the efficacy and safety of anti–miR-33 therapy.
In this study, we assessed the differences between miR-
33a and miR-33b in vitro and in vivo using genetically
modified miR-33a knockout and miR-33b knock in (KI) mice,
reported previously.10,19 The organ distributions of these 2
miRs were different. In particular, the 2 most atherosclerosis
responsible organs, macrophages and liver, showed distinct
patterns of distribution of miR-33a or miR-33b. Moreover,
through modification of the dietary cholesterol burden, we
found that these 2 miRs are strictly and distinctly regulated by
cholesterol burden. In particular, miR-33b was induced by
high dietary fat and cholesterol, which is a common compo-
sition of current diets and is considered to be atherogenic.
Overall, the apolipoprotein E–deficient (ApoE/) mice with
only miR-33b showed greater atherosclerotic burden than
ApoE/ mice with only miR-33a. These data suggest that




We crossbred previously generated miR-33 knockout mice and
miR-33b KI mice and obtained 4 genetically modified mice. In
this article, we named miR-33a+/+ and miR-33b/ as miR-33
wild-type (WT) mice and miR-33a/ and miR-33b+/+ as miR-
33 knock out knock in (KOKI) mice. We used male mice for all
the experiments, except for bone marrow transplantation
experiments. To assess the expression pattern of miR-33a and
miR-33b with a Western-type diet (WTD) containing 0.15%
cholesterol and 40% fat (Oriental Yeast, Japan) feeding, we fed
8-week-old miR-33b KI mice with WTD for 4 weeks. For
cholesterol-lowering experiments, miR-33b KI mice were
placed on WTD and in the second week, 10 mg/kg body
weight pitavastatin (KOWA, Japan) and ezetimibe (Santa Cruz,
TX) dissolved in carboxymethyl cellulose were administrated by
oral gavage every 24 hours for 7 days. Mice were euthanized
24 hours after the last administration. For the plaque forma-
tion analysis, we also obtained ApoE/ miR-33a WT and
ApoE/ miR-33 KOKI mice by crossbreeding. These mice are
weaned at the age of 4 weeks and fed normal chow (Oriental
yeast) and switched to WTD at 6 weeks of age, until 18 weeks
Clinical Perspective
What Is New?
• This is the first report of the assessment of the atherogenicity
of microRNAs (miR-33a and miR-33b) separately in vitro and
in vivo using genetically modified mice. We found that miR-
33b showed increased atherogenic potential.
• Both miR-33a and miR-33b showed differential expression
in various organs and were antagonistically regulated by
whole-body cholesterol burden.
• The miR-33b showed dominant expression in the liver, and
its expression was enhanced in response to cholesterol
overload. This resulted in the increased atherogenicity under
the high-fat and high-cholesterol diet in the apolipoprotein
E–deficient/miR-33a//miR-33b+/+ mice.
What Are the Clinical Implications?
• The inhibition of miR-33 is considered as a promising
antiatherogenic therapy. Because complete deletion of miR-
33 causes obesity and fatty liver in mice, miR-33b–specific
inhibition may serve as an alternative approach for thera-
peutic miR-33 inhibition.
• Statins reduced the hepatic total miR-33 copy number in
mice. It might be one of potential causes of pleiotropy of
statins.
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of age. Aortic root frozen sections were stained with oil-red O,
picrosirius red, anti-CD68 antibody (1 lg/mL), and anti–ATP-
binding cassette A1 (ABCA1; 2 lg/mL; NB400-105; Novus
Biologicals); and the positive area was quantified by Adobe
Illustrator and in-house R script. Polymerase chain reaction
(PCR) primers used in genotyping PCR are provided in Table S1.
Mice were euthanized by the IP injection of pentobarbital
(50 mg/kg body weight; Kyoritsu Seiyaku, Japan), followed by
cervical dislocation. Anesthesia was achieved by continuous
inhalation of sevoflurane or IP injection of mixed anesthesia
consisting of medetomidine (0.3 mg/kg body weight; Nihon
Zen-yaku, Japan), midazolam (4 mg/kg body weight; Sandoz,
Japan), and butorphanol (4 mg/kg body weight; Meiji Seika
Pharma, Japan). This study was approved by the Kyoto
University Ethics Review Board. All methods were performed
in accordance with the relevant guidelines.
Cell Culture
Primary hepatocytes were obtained from miR-33 knockout
mice by the collagenase perfusion method. Livers from mice
were lysed by retrograde perfusion with collagenase type II
(Worthington, OH). The cell suspension was passed through a
70-lm cell strainer and centrifuged to isolate mature
hepatocytes. Hepatocytes were seeded onto collagen type-I
coated dishes at a density of 2.59105 cells/mL in Dulbecco’s
modified Eagle’s medium low glucose (Nacalai Tesque, Japan)
supplemented with 10% fetal bovine serum (FBS). Primary
mouse peritoneal macrophages were obtained from miR-33
WT, miR-33a knockout, miR-33b KI, and miR-33 KOKI mice by
intraperitoneal lavage with cold phosphate-buffered saline
(PBS) 72 hours after the intraperitoneal administration of 3%
(w/v) thioglycolate. Macrophages were resuspended in RPMI
Figure 1. Similarities and differences between microRNAs (miR-33a and miR-33b). A, Genomic loci of
sterol regulatory element-binding factor (SREBF) 2/miR-33a and SREBF1/miR-33b in the human genome.
B, Reference sequence, seed sequence, and targeting sequence of miR-33a and miR-33b. UTR indicates
untranslated region.
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1640 medium (Nacalai Tesque) containing 10% FBS, and
seeded at a density of 5.09105 cells/mL. Hep-G2 cells were
cultured with DMEM supplemented with 10% FBS at a density
of 1.09106 cells/mL. For cholesterol-depletion experiments,
the medium was replaced with DMEM containing 10%
lipoprotein-depleted serum and 10 nmol/L pitavastatin.
Gene Expression Analysis by Quantitative
Real-Time PCR
Total RNA was isolated using TriPure reagent (Sigma-Aldrich,
MO) from organs or cells. For coding genes, cDNA was
synthesized using a Verso cDNA synthesis kit (Thermo Fisher
Scientific, MA) and quantitative real-time PCR was performed
with THUNDERBIRD SYBR qPCR MIX (TOYOBO, Japan) in
accordance with the manufacturer’s instructions. Expression
levels were normalized using the b-actin expression level.
Primers used in this study are listed in Table S2. For miR,
quantitative PCR was performed using TaqMan MicroRNA
Assays (Applied Biosystems, CA) in accordance with the
manufacturer’s instructions. Expression levels were normal-
ized by U6 small nuclear RNA expression or quantified by the
standard curve method. Both analyses were performed using
a StepOnePlus real-time PCR system (Applied Biosystems).
Western Blotting
Western blotting analysis was performed as described previ-
ously.17 Proteins were fractionated using NuPAGE 4% to 12%
Bis-Tris gels (Invitrogen) and transferred to Protran nitrocellu-
lose transfer membrane (Whatman, Japan). The membrane was
blocked using PBS containing 5% nonfat milk for 30 minutes at
room temperature and incubated with the primary antibody
(anti-ABCA1: 1:2000, NB400-105; anti-ABCG1 (anti-ATP bind-
ing cassette G1): 1:2000, NB400-132 [Novus Biologicals, CO],
anti–carnitine palmitoyltransferase Ia: 1:2000, ab128568
[Abcam, UK]; anti–b-actin: 1:3000, A5441 [Sigma-Aldrich])
overnight at 4°C. Themembrane was washed in PBS containing
0.05% Tween-20, and then it was incubated with the secondary
antibody (anti-rabbit IgG horseradish peroxidase linked:
1:2000; anti-mouse IgG horseradish peroxidase linked:
1:2000 [GE Healthcare, UK]) for 30 minutes at room temper-
ature. The membrane was washed in PBS containing 0.05%
Tween-20 and incubated with ECL Western Blotting Detection
Reagent (GE Healthcare) for 5 minutes; then, the signal was
detected using an LAS-4000 system (Fuji Film, Japan).
Glucose and Insulin Tolerance Test
For the glucose tolerance test, 12-week-old miR-33 WT mice
and miR-33 KOKI mice were starved overnight; then, 1.0 g/kg
body weight glucose was administrated by IP injection. For
the insulin tolerance test, miR-33 WT mice and miR-33 KOKI
mice were starved for 4 hours; then, 1 U/kg body weight
insulin was administrated by IP injection. Blood was obtained
from the cut tail, and glucose concentrations were measured
by a glucose sensor at each time point.
Metabolomic Analysis
The 8-week-old miR-33 WT, knockout, or KI mice liver samples
were subjected to capillary electrophoresis–time-of-flight
mass spectrometry, capillary electrophoresis–triple quadru-
pole mass spectrometry, and liquid chromatography–time-of-
flight mass spectrometry analyses (Agilent, Palo Alto, CA) and
quantified by Human Metabolome Technologies, Inc.
miR-Target Metabolite Integrating Pathway
Analysis
Significantly dysregulated metabolites in miR-33 KI mice liver
were determined by t test for log-transformed metabolite
abundance. To integrate miR-33 target gene information, we
downloaded the predicted miR-33 target site of mouse from
the TargetScan website (http://www.targetscan.org/mmu_
71). We performed gene-metabolite integrated pathway
analysis by Integrated Molecular Pathway Level Analysis
framework (http://impala.molgen.mpg.de/impala/), by intro-
ducing these dysregulated metabolites and predicted miR-33
targets. Pathways with a false discovery rate <0.05 are
shown.
miR Transcriptome Analysis in the miR-33
Knockout Mice
Liver total RNA was extracted from 8-week-old miR-33
knockout mice and WT mice using TriPure reagent in
accordance with the manufacturer’s instructions. Whole miR
transcriptome analysis was performed using miRNA Oligo chip
(mouse, v19; TORAY, Japan).
Transcriptomic Analysis of miR-Transfected
Primary Hepatocytes
At 24 hours after incubation in DMEM supplemented with
10% FBS, the primary hepatocytes were transfected with miR-
33a, miR-33b, or control-miR mimic (Thermo Fisher Scientific)
at a concentration of 30 nmol/L using Lipofectamine 2000
(Thermo Fisher Scientific) in accordance with the manufac-
turer’s instructions. Total RNA was extracted using TriPure
reagent in accordance with the manufacturer’s instructions.
Whole transcriptome analysis was performed using Gene-
ChipMouseGene2.0ST Arrays (Affymetrix, CA). 30-Untrans-
lated region sequences were obtained from bioMart (https://
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www.ensembl.org/biomart) and analyzed using an in-house
script. Motif enrichment analysis was performed using
Sylamer software.20 Differences of the expression patterns
between transcripts with different miR-33 targeting motif
were tested by Kolmogorov-Smirnov test.
Cholesterol Efflux Via Mouse Apolipoprotein B
Depleted Serum
Cholesterol efflux capacity of mouse apolipoprotein B depleted
serum was measured as previously described.21 Briefly, J774
mouse macrophage cells were seeded at a density of
79104 cells/well in a 24-well dish. These cells were labeled
with 2 lCi/mL 3H-cholesterol for 24 hours in RPMI 1640
medium with 1% FBS. Then, cells were incubated for 16 hours
in RPMI 1640 medium containing 8-(chlorophenylthio) adeno-
sine 30,50-cyclic monophosphate (0.3 mmol/L) and 0.2% BSA
to upregulate ABCA1 in J774 cells. After washing 4 times with
RPMI 1640 medium, cells were incubated with serum
containing 2.8% apolipoprotein B depleted mouse serum.
Apolipoprotein B depletion was achieved by polyethylene
glycol. Cholesterol extraction properties were quantified as
the percentage of radioactivity from the cells divided by the
total radioactivity from the cells and medium.
Cholesterol Efflux From Mouse Peritoneal
Macrophages
Cellular cholesterol efflux via apolipoprotein A-1 and HDL was
determined as described previously.10 Briefly, thioglycolate-
elicited mouse peritoneal macrophages were plated in 48-well
dishes (2.59106 cells/mL) and were cultured for 24 hours in
RPMI 1640 medium containing 3H-labeled acetylated low-
density lipoprotein (1.0 lCi/mL of 3H-cholesterol and 25 lg/
mL of acetylated low-density lipoprotein; Biomedical Tech-
nologies Inc, MA). Cells were washed 4 times with medium
and then incubated for 6 hours in RPMI 1640 medium with or
without apolipoprotein A-1 and HDL at indicated concentra-
tions. Cholesterol efflux was expressed as a percentage of the
radioactivity released from cells in medium relative to the
total radioactivity in cells and medium.
Quantification of Cholesterol and Triglyceride in
the Mouse Liver
Lipids in the liver were extracted by the Folch method, as
previously described.17 Briefly, the lipids in the liver were
extracted by addition of ice-cold MeOH, followed by CHCl3.
Water was added to the sample and incubated on ice for an
additional 10 minutes, with occasional mixing. The sample was
centrifuged for 5 minutes at 2000g, and the aqueous phase
was discarded and reextracted by addition of ice-cold CHCl3:
MeOH (2:1, v/v). Organic phases were collected and dried
under nitrogen stream. Lipids were quantified using the
Cholesterol E-test (WAKO, Japan) or Triglyceride E-test (WAKO).
Bone Marrow Transplantation
Bone marrow transplantation experiments were performed
using the same protocol as reported previously.14 Eight-week-
old male miR-33 WT or miR-33 KOKI mice were used as bone
marrow donors. Recipients were 8-week-old miR-33 WT female
mice. All mice used for bone marrow transplantation experi-
ments had an ApoE/ background. After euthanasia by
cervical dislocation, femurs and tibias of donor mice were
flushed with PBS containing 3% FBS and bone marrow cells
were collected. The cell suspension was passed through a 40-
lm cell strainer, and contaminating red blood cells were lysed
using ACK lysing buffer (Lonza, Switzerland). Bonemarrow cells
were washed twice with 3% PBS and suspended in RPMI 1640
medium. For donor mice, to induce bone marrow aplasia, whole
body irradiation was performed twice, using 6 Gy, within an
interval of 3 hours (137Cs; Gammacell 40 Exactor), and
prepared bone marrow cells were transferred by retro-orbital
injection with 59106 bone marrow cells 6 hours after irradi-
ation. Transplantedmice were placed on a standard normal diet
for 4 weeks, and then switched to WTD for 12 weeks.
Reporter Assay
A complementary sequence of miR-33a or miR-33b was
subcloned into psiCheck2 (Promega, WI) vector. Then, 50 ng
of the reporter constructs was transfected into HepG2 cells
with miR mimic at 1 nmol/L. At 24 hours after transfection,
the cells were lysed and analyzed using a Piccagene dual
luciferase reporter assay system (Toyo INK, Japan). Subse-
quently, 50 ng of liver-X-receptor (LXR) element reporter
construct and sterol regulatory element reporter construct
were transfected into HepG2 cells and incubated for 24 hours
in the indicated medium composition.
Statistical Analysis
Numerical data are expressed as the meanSEM. In the dot
plots, horizontal bars indicate meanSEM. Two sample data
sets were tested using a 2-tailed Student t test or a Wilcoxon
rank sum test. The normality was tested beforehand by the
Kolmogorov-Smirnov normality test. If deviation from normal-
ity was observed, we applied a nonparametric test for the data
set. For multiple comparisons, one-way analysis of variance
followed by Tukey and Dunnett multiple comparisons was
used. P<0.05 was considered statistically significant. Data
analyses and statistical tests were performed using R, version
3.3.1, and Prism, version 6.0 (GraphPad Software).
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Similar Potential Target Repression and Targeting
Motif of miR-33a/b in Vitro
To explore the similarities and differences in the targeting
potency, and the target motifs of miR-33a and miR-33b, we
performed transcriptomic analysis of primary cultured hepato-
cytes transfected with synthetic miR-33a, miR-33b, and a
control miR (Figure 2A). To avoid the effects of endogenous
miR-33, hepatocytes were obtained from miR-33a//miR-
33b/ (referred to as miR-33a knock-out) mice that were
generated previously.9 The systemic miR expression remodel-
ing in the liver of these mice was not observed (Figure S1).
Hierarchical clustering analysis revealed that the gene expres-
sion signature of hepatocytes transfected with miR-33a and
miR-33b formed a tight cluster that was distinct from the
control (Figure 2B). To identify the difference between the
target motifs, we performed the motif enrichment analysis in
the 30-untranslated region (Figure 2C). We found that genes
with miR-33 canonical targeting sites were significantly
repressed by synthetic miR-33a and miR-33b. However, we
found no significantly repressed motifs in the comparison
between miR-33a and miR-33b. This result suggested that miR-
33a and miR-33b target virtually the same genes. These 2
synthetic miRs showed significant repression effects specifi-
cally on the genes with canonical miR-33 targeting sites in the
30-untranslated region (Figure 2D). However, the repression
potency of both these miRs showed no significant difference.
Distinct Organ Distribution Patterns of miR-33a
and miR-33b in Vivo
Because the targeting potency and targeting motif were
relevant, we examined the spatial distributions of these 2
miRs. We obtained organs and thioglycolate-elicited peritoneal
macrophages frommice carrying the humanmiR-33b sequence
in Srebf1 intron 16 (miR-33a+/+/miR-33b+/+, referred to as
miR-33b knock in), which were reported previously.19 We found
distinct expression patterns of miR-33a and miR-33b in several
organs (Figure 3A). In particular, in the 2 most atherosclerosis-
responsive organs, macrophages and liver, the expression
patterns showed distinct contrasts. In peritoneal macrophages,
miR-33a and miR-33b were relevant, but in the liver, miR-33b
showed higher copy number than miR-33a. Each intronic miR is
coexpressedwith its host gene. The expression patterns ofmiR-
33a and miR-33b were closely correlated with those of Srebf2
and Srebf1 expression, respectively. To confirm its relevance in
humans, we analyzed the expression patterns of these host
genes and miR-33 family in FANTOM5 human primary cultured
cells.22,23 We also found distinct expression patterns of the
miR-33 family and significant correlation between SREBF2 or
SREBF1 and miR-33a or miR-33b (Figure 3B and 3C).
To dissect the functional difference in the different abun-
dance ofmiR-33a andmiR-33b in vivo, we generated 4 strains of
mice in whichmiR-33a and/ormiR-33bwas specifically deleted
by cross bleeding of miR-33a knockout and miR-33b KI mice
(Figure 4A). These mice were born at mendelian ratio and did
not show significant differences in body weight or liver weight
(Figure 4B) at 8 weeks old. Previous studies confirmed the role
of the miR-33 family in cholesterol metabolism. Therefore, we
assessed the serum cholesterol profile of these 4 strains of
mice (Figure 4C). The level of serum HDL-cholesterol was the
highest in miR-33a knockout mice and lowest in miR-33b KI
mice, as expected. Interestingly, the miR-33a//miR-33b+/+
(referred to as miR-33 KOKI) mice showed significantly
decreased serum HDL-cholesterol levels compared with miR-
33a+/+/miR-33b/ (referred to as miR-33 WT) mice by30%,
and as low as miR-33b KI mice. Hereafter, we mainly compared
WT with KOKI mice because we want to clarify the in vivo
functional difference between miR-33a and miR-33b. We
assessed the absolute quantity of miR-33 family in the liver
and found dominant abundance of miR-33b (Figure 4D).
Although the expression of host genes was similar, the
confirmed miR-33 target genes were significantly repressed
(Figure 4E through 4G). In addition, we noticed a slightly
reduced LDL-cholesterol level in miR-33 KOKI than miR-33 WT
mice; however, genes involved in LDL-cholesterol metabolism
showed no significant difference between miR-33 KOKI and
miR-33 WT mice (Figure 4H).
As previous reports suggested the roles ofmiR-33 in glucose
homeostasis, we assessed glucose and insulin tolerance of the
2 strains of mice as potential atherogenic factors. We found
significantly impaired glucose tolerance and decreased insulin
sensitivity (Figure 5A) of miR-33 KOKI mice than miR-33 WT
mice. In addition, we performed metabolomic analysis of the
liver tissue in miR-33 knockout, miR-33 KI, and WT mice. We
found that a greater number of metabolites showed different
abundance compared with miR-33 WT in the miR-33 KI mice
liver than miR-33 knockout mice liver (Figure 5B). To charac-
terize the metabolomic changes caused by miR-33b, we also
performed integrated pathway enrichment analysis of these
metabolites and miR-33 target genes. We identified several
pathways on which these metabolites and miR-33 target genes
were enriched. These pathways included glucose homeostasis
related pathways (Figure 5C and Figures S2 through S4).
Relevant Functions of miR-33a and miR-33b in
Macrophages
Because miR-33 in macrophages was also shown to be
responsible for atherosclerosis, especially by repressing
cholesterol reverse transport, we assessed the function of
macrophages, where the abundance of miR-33a and miR-33b
was relevant (Figure 3A). To assess the functional differences
DOI: 10.1161/JAHA.119.012609 Journal of the American Heart Association 6















in macrophages obtained from these 4 strains of mice, we
performed cholesterol efflux experiments. The experiments
confirmed the similar functionality of macrophages obtained
frommiR-33WT andmiR-33 KOKI mice (Figure 6A). Supporting
this result, gene expression analysis confirmed no significant
difference in the expression of Abca1 or Abcg1 in macrophages
obtained from miR-33 KOKI mice compared with miR-33 WT
mice (Figure 6B and 6C). Although previous reports also
Figure 2. Transcriptomic analysis of targeting potency and targeting motifs in rodent primary
hepatocytes. A, Experimental schema. B, Hierarchal clustering analysis of the expression pattern of
primary hepatocytes. MicroRNAs (miR-33a and miR-33b) indicate miR-33a or miR-33b transfected primary
hepatocytes. n=2 for each. C, Significantly suppressed motifs by synthetic miR transfection. miR-33a vs
miR-control (left), miR-33b/miR-control (middle), and miR-33a/miR-33b (right). Dotted lines indicate
significant threshold after multiple testing correction. D, Suppression of mRNAs with or without miR-33
target sites in their 30-untranslated region. P values were calculated using the Kolmogorov-Smirnov test.
7-mer-A1 indicates CAAUGCA; 7-mer-m8, AAUGCAA; 8-mer, CAAUGCAA; KO, knock out.
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suggested the participation of miR-33 in macrophage inflam-
matory phenotypes,15,16 inflammatory gene expression pat-
terns were similar between macrophages obtained from miR-
33 KOKI mice compared with miR-33 WT mice (Figure 6D).
Regulation of the miR-33 Family in Cholesterol-
Burdened Conditions
Intronic miRs are expressed concurrently with their host
genes. Srebf2, the host gene of miR-33a, is the master
regulator of cholesterol homeostasis. Decreased cellular
cholesterol content enhances the activity of the sterol
regulatory element-binding protein 2 and increases the
expression of the sterol regulatory element-binding protein 2
target genes. On the contrary, Srebf1, the host gene of miR-
33b, is regulated by transcriptional regulation through the LXR.
The activity of the LXR axis is enhanced by increased cellular
cholesterol content. To assess the effect of hypercaloric and
hypercholesteric diet on the expression of miR-33a and miR-
33b, we fed miR-33b KI mice with WTD (Figure 7A). Feeding
the miR-33b KI mice with WTD for 4 weeks successfully
induced a hypercholesterolemic state (Figure 7B), resulting in
a reduction in Srebf2 expression and an increase in Srebf1
expression (Figure 7C). Corresponding to these changes in the
expression of host genes, reduced miR-33a and increased miR-
33b expression levels were observed in the liver (Figure 7D);
and these changes were accompanied by changes in the
expression patterns of sterol regulatory element-binding
protein 2/LXR target genes (Figure 7E).
Regulation of the miR-33 Family in Cholesterol-
Depleted Conditions
Cholesterol-lowering treatment is the established therapeutic
approach against atherosclerotic disease and is generally used
in the clinical setting. In such conditions, the enhanced
Figure 3. Organ expression patterns of microRNAs (miR-33a and miR-33b) and sterol regulatory element-binding factor (Srebf) 1 and Srebf2. A,
Absolute copy number of miR-33a and miR-33b (left) and correlations between the expression ratios of miR-33a/miR-33b and Srebf2/Srebf1 in
organs of miR-33b KI mice (right). n=3 for each organ. B, miR-33 family abundance in human primary culture cells. C, Correlations between Srebf2
and miR-33a (left) and Srebf1 and miR-33b (right) expression levels in human primary cultured cells. Pearson’s correlation coefficients (r) and P
value were shown. Horizontal bars in the dot plots indicate meanSEM. PMP indicates peritoneal macrophage; WAT, white adipose tissue; cpm,
counts per million.
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Figure 4. Generation, phenotype, and gene expression of microRNA (miR)-33 wild-type (WT) and miR-33 knock out
knock in (KOKI) mice. A, Representative polymerase chain reaction (PCR) genotyping results and nomenclatures of the
4 strains of mice. B, Body and liver weight of 8-week-old miR-33 4 strain mice. n=5 for knockout, n=5 for WT, n=6 for
KOKI, and n=6 for KI for body weight. n=5 for knockout, and n=4 for WT, KOKI, and KI for liver weight. C, Serum lipid
levels of the 4 strains of mice. n=13 for knockout, n=24 for WT, n=24 for KOKI, and n=14 for KI. D, Absolute copy
number of miR-33a and miR-33b in miR-33 WT mice and miR-33 KOKI mice liver. n=4 for each. E, Quantitative PCR
analysis for miR-33 host and target genes in the liver. F, Densitometric analysis of Western blotting of miR-33 target
genes in the liver. G, Representative Western blotting images of miR-33 target genes in the liver. H, Quantitative PCR
analysis for low-density lipoprotein-cholesterol (LDLC) related genes in the liver. n=5 for WT, and n=6 for KOKI.
Horizontal bars in the dot plots indicate meanSEM. ABCA indicates ATP-binding cassette A; HDLC, high-density
lipoprotein-cholesterol; T-Chol, total cholesterol; ACTB, Beta acitin; CPT, Carnitine Palmitoyltransferase; KO, Knock out;
TG, Triglyceride. *P<0.05 compared with WT.
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expression of miR-33a was suggested; however, there was no
evidence of the kinetics of miR-33b in such conditions. To
assess changes in the expression of miR-33a and miR-33b
under these conditions, we performed cholesterol-lowering
experiments in vivo. We administrated statin or vehicle orally
to WTD-fed miR-33b KI mice (Figure 8A). Because the dietary
cholesterol intake was not negligible in mice, we also
administrated intestinal cholesterol absorption inhibitor, eze-
timibe, simultaneously. This treatment effectively decreased
serum LDL-cholesterol levels without affecting the body, liver,
and adipose tissue weight of WTD-fed miR-33b KI mice
(Figure 8A and 8B); and it significantly repressed Srebf1 and
miR-33b expression in the liver (Figure 8C and 8D). Indeed, the
miR-33a expression levels were also significantly increased;
considering the prevalence of miR-33b in the liver, the hepatic
total miR-33 copy number was significantly decreased by the
treatment. Changes in cellular sterol regulatory element and
LXR element signaling by statin treatment were also confirmed
by reporter assays using the HepG2 human liver cell line
(Figure 8E). These transcriptional changes in the miR-33 family
were also accompanied by changes in the expression patterns
of sterol regulatory element-binding protein 2/LXR target
genes in the opposite direction to WTD-fed mice (Figure 8F).
These transcriptional changes resulting from the statin/
ezetimibe treatment were replicated in human primary
cultured hepatocytes24 (Figure 8G).
Figure 5. Impaired glucose tolerance and dysregulated liver metabolites in microRNA (miR)-33 knock out knock in (KOKI) mice. A, Glucose
and insulin tolerance of miR-33 wild-type (WT) and miR-33 KOKI mice. n=6 for WT, and n=5 for KOKI. *P<0.05 compared with WT. B, Number of
significantly dysregulated metabolites for miR-33 knockout mice compared with WT and miR-33b KI mice compared with WT mice. n=6 for each.
*P<0.05 compared with knockout (tested by Fisher’s exact test). C, Significantly dysregulated pathways in miR-33b KI mice liver. Horizontal bars
in the line chart or dot plots indicate meanSEM. AMPK indicates AMP kinase; AUC, area under the curve; FDR, false discovery rate; IPGTT,
intraperitoneal glucose tolerance test; IPITT, intraperitoneal insulin tolerance test; KO, Knock out.
DOI: 10.1161/JAHA.119.012609 Journal of the American Heart Association 10















Differential Roles of miR-33a and miR-33b in
Atherosclerotic Plaque Formation
From the data presented above, miR-33a and miR-33b had
similar targeting potency and targeting genes; however, the
organ distribution was different. To compare the whole body
atherogenic potency of miR-33a and miR-33b, we generated
ApoE//miR-33 WT and ApoE//miR-33 KOKI mice. When
fed a WTD for 12 weeks, ApoE//miR-33 KOKI mice
showed higher plaque burden than ApoE//miR-33 WT
mice (Figure 9A through and 9C). Serum HDL-cholesterol
level was reduced in ApoE//miR-33 KOKI mice versus
ApoE//miR-33 WT mice (Figure 9D and 9E). As reported
previously in miR-33b KI mice, reduced serum triglyceride
levels in miR-33 KOKI mice were also observed. To confirm
that reduced serum HDL-cholesterol level resulted in
increased atherogenicity in ApoE/ miR-33 KOKI mice, we
assessed cholesterol extraction properties of serum obtained
from these 2 strains of mice. According to the difference in
serum HDL-cholesterol levels, the serum obtained from
ApoE/ miR-33b KOKI mice showed significantly decreased
cholesterol extraction property than the serum obtained from
ApoE/ miR-33 WT mice (Figure 9F). In addition, the miR-33
KOKI mice showed blunted dose relationships between serum
HDL-cholesterol content and cholesterol efflux properties
compared with WT mice. Moreover, the miR-33 KOKI mice
showed significantly reduced miR-33 target gene expression
in the liver (Figure 9G and 9H). This finding was consistent
with the higher expression of miR-33b than miR-33a in mice
livers. These results suggest that miR-33b is more responsible
for atherogenesis in vivo than miR-33a, especially through the
dysregulation of hepatic gene expression and worsened
serum cholesterol profile. Because a previous report impli-
cated the role of miR-33 in cholesterol accumulation and
inflammation in the liver, we assessed the liver triglyceride or
cholesterol content and liver injury marker in the ApoE/
WTD-fed study. We observed a significant increase in the
triglyceride content and a nonsignificant increase in the
cholesterol content of the liver in ApoE//miR-33 KOKI
mice compared with those in ApoE//miR-33 WT mice.
Accordingly, a nonsignificant increase in the serum aspartate
transaminase/alanine aminotransferase levels and a
Figure 6. Similar characteristics of peritoneal macrophages obtained from microRNA (miR)-33 wild-type (WT) and miR-33 knock out knock in
(KOKI) mice. A, Cholesterol efflux to high-density lipoprotein (HDL) or apolipoprotein A-1 (ApoA-1) from peritoneal macrophages from the 4 strains
of mice. n=8 for each. B, Quantitative polymerase chain reaction (PCR) analysis for miR-33 target genes in the peritoneal macrophages. n=7 for
each. C, Representative images of Western blotting analysis for miR-33 target genes in the peritoneal macrophages. n=6 for each. D, Quantitative
PCR analysis for inflammatory markers in the peritoneal macrophages. n=7 for each. Horizontal bars in the dot plots indicate meanSEM. ABCA
indicates ATP-binding cassette A; ABCG1, anti ATP binding cassete G1; ACTB, beta-actin; KO, Knock out. *P<0.05 compared with WT.
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significant increase in hepatic gene expression of inflamma-
tory makers were observed in ApoE//miR-33 KOKI mice
(Figure 9I through 9K).
To further characterize the atherogenic plaque, we per-
formed the immunostaining of CD68 and ABCA1; and we
could not detect significant differences of the positive area
Figure 7. Changes in liver gene expression in microRNA (miR)-33b knock in (KI) mice in the cholesterol-burdened condition. A, Experimental
scheme and changes in body, liver, and epidydimal white adipose tissue (EpiWAT) weight during experiment. B, Serum lipid profiles after
2 weeks of Western-type diet (WTD) feeding experiment. Quantitative polymerase chain reaction analysis for sterol regulatory element-binding
factor (Srebf) 2 and Srebf1 (C) and miR-33a and miR-33b (D) in the liver under the cholesterol-burdened condition. E, Heat map representation
of liver gene expression levels of mice fed normal chow (NC) or WTD. n=3 for normal NC-fed mice, and n=4 for WTD-fed mice. Horizontal bars in
the dot plots indicate meanSEM. EC indicates esterified cholesterol; FC, free cholesterol; HDLC, high-density lipoprotein-cholesterol; LDLC,
low-density lipoprotein-cholesterol; T-Chol, total cholesterol; TG, Triglyceride. *P<0.05 compared with NC-fed mice.
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(Figure 10A and 10B). In addition, because a previous report
suggested the role of miR-33b in the unstable plaque
formation,21 we assessed the area of picrosirius red staining.
However, we also could not detect any difference in the area
of unstable plaque. To compare the function of macrophages
of these 2 genotypes in vivo, we performed bone marrow
transplantation experiments using these 2 strains (Fig-
ure 11A). As a result, the genotype of miR-33 in bone marrow
did not affect the atherosclerotic lesion size (Figure 11B and
11C). In addition, no significant changes in serum lipid profile
were detected between these 2 groups (Figure 11D). This
result was consistent with the similar prevalence of miR-33a
and miR-33b observed in the mice macrophages.
Discussion
In the current study, we comprehensively analyzed the
differential roles of miR-33a and miR-33b in various physio-
logical conditions and during the progression of atheroscle-
rosis using genetically modified mice in detail. In vitro
transcriptomic assays confirmed the similar functionality of
miR-33a and miR-33b. However, in vivo, these miRs were
differently distributed and regulated. The cholesterol burden
of the body regulated these miRs differently, especially when
fed an atherosclerosis-prone diet, which contained high fat
and high cholesterol, resulting in significantly increased miR-
33b expression in the liver through the enhancement of the
Figure 8. Changes in liver gene expression in microRNA (miR)-33b knock in (KI) mice in the cholesterol-depleted condition. A, Experimental
scheme and changes in body liver and epidydimal white adipose tissue (EpiWAT) weight during experiment. B, Serum lipid profiles after 2 weeks of
Western-type diet (WTD) feeding and 1 week of treatment with vehicle or statin/ezetimibe. C and D, Quantitative polymerase chain reaction
analysis for sterol regulatory element-binding factor (Srebf) 2 and Srebf1 (C) and miR-33a and miR-33b (D) in the liver under the cholesterol-
depleted condition. n=4 for each. *P<0.05 compared with vehicle. E, Reporter assay containing sterol response element (SRE) and liver-X-receptor
response element (LXRE) in HepG2 cells. n=3 for each. *P<0.05 compared with fetal bovine serum (FBS) containing medium. F, Heat map
representation for liver gene expressions of mice treated with vehicle or statin/ezetimibe. Green indicates low expression level, and red indicates
high expression level. n=4 for each. G, Heat map representation of gene expression in vehicle- or statin-treated human primary culture
hepatocytes. Data were obtained from GSE24187. n=6 for each. Horizontal bars in the dot plots indicate meanSEM. HDLC indicates high-density
lipoprotein-cholesterol; LDLC, low-density lipoprotein-cholesterol; LPDS, lipoprotein-depleted serum; T-Chol, total cholesterol; TG, Triglyceride.
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LXR signaling axis. On the contrary, statins, which are
commonly used as antiatherosclerotic drugs, reduced expres-
sion of miR-33b in the liver. miR-33 KOKI mice showed
increased plaque formation versus miR-33 WT mice. From
these data, we considered that miR-33b could be more
responsible for the atherosclerotic plaque formation in vivo.
We showed that miR-33a and miR-33b play distinct
biological roles in vivo. As expected from the targeting
mechanisms of miRs,25 the result of our transcriptomic
evaluation using miR-33–null hepatocytes and artificially
synthesized miRs confirmed the same functionalities of miR-
33a and miR-33b in repressing the target gene expression.
Figure 9. Increased atherosclerotic plaque burden in apolipoprotein E–deficient (ApoE/)/microRNA (miR)-33 knock out
knock in (KOKI) mice. Representative microscopic images of the en-face analysis of aortic atherosclerotic plaque (A) and
proximal aorta (B) in ApoE//miR-33 wild-type (WT) mice and ApoE//miR-33 KOKI mice. Bar=500 lm. C, Quantification
of the atherosclerotic plaque area in cross-sections at the proximal aorta level. D, Serum lipid profiles of ApoE//miR-33
WT mice and ApoE//miR-33 KOKI mice. n=14 for WT, and n=10 for KOKI. E, High-performance liquid chromatography
analysis of serum cholesterol and triglyceride levels from ApoE//miR-33 WT mice and ApoE//miR-33 KOKI mice. F,
Cholesterol extraction properties of serum obtained from ApoE//miR-33 WT or ApoE//miR-33 KOKI mice (left) and
correlations between serum high-density lipoprotein-cholesterol (HDLC) level and cholesterol efflux (right). n=11 for WT, and
n=9 for KOKI. G, Quantitative polymerase chain reaction (PCR) analysis for miR-33 target genes in the liver. H, Western blot
analysis for miR-33 target genes in the liver. b-Actin is used as loading control. I, Quantifications of triglycerides or
cholesterol content in the liver. n=6 for each. J, Serum aspartate transaminase (AST) and alanine aminotransferase (ALT)
levels from ApoE//miR-33 WT and ApoE//miR-33 KOKI mice. n=14 for WT, and n=10 for KOKI. K, Quantitative PCR
analysis for gene expression of inflammatory makers in the liver. n=6 for each. Horizontal bars in the dot plots indicate
meanSEM. ApoB indicates apolipoprotein B; LDLC, low-density lipoprotein-cholesterol; T-Chol, total cholesterol; WTD,
Western-type diet; TG, Triglyceride. *P<0.05 compared with WT.
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Although there are many reports focusing on the biological
function or disease relevance of miRs as a family, reports
focused on the difference among members of an miR family
are rare. One example is the miR-1/miR-133a and miR-133b/
miR-206 cluster. miR-1 and miR-206 share a common seed
sequence, as do miR-133a and miR-133b. These miR families
show distinct organ distribution and involvement in different
biological processes.26 In addition, members of the same miR
family may show distinct biological functions through their
distinct subcellular localization.27 In line with these data, the
observed differences between miR-33 WT and miR-33 KOKI
mice in this study are also based on the different spatiotem-
poral localizations. From these observations, we believe that a
comprehensive assessment of the spatiotemporal distribution
is important to understand the precise functionality of miRs.
In particular, the experiments using genetically modified mice
gave us clear data, and these data are also important to
establish an effective and safe therapeutic approach.
In this study, the miR-33 KOKI mice exhibited increased
plaque formation versus miR-33 WT mice. This result was
reasonable because miR-33b was more abundant than miR-
33a in the liver; on the other hand, miR-33a and miR-33b were
relevant in macrophages. Because previous reports showed
that whole-body miR-33 knockdown resulted in attenuated
atherosclerosis through functional changes in these
organs,11,14,28–31 we considered that our result is consistent
with these observations. In addition, enhanced expression of
miR-33b with a cholesterol-rich diet could also contribute to
the worsening of atherogenic phenotype in the miR-33 KOKI
mice. From these observations, we considered that miR-33b
is a more potent therapeutic target of miR-33–repressing
therapy against atherosclerotic disease than miR-33a. The
deletion of miR-33a results in worsened conditions in several
cases, including not only obesity and glucose intolerance, as
mentioned above, but also reduced cardiac function in
pressure overload conditions in our previous report.32 Non-
selective miR-33 inhibition may cause such adverse effects
through the repression of miR-33a, especially in miR-33a
dominant organs. Considering this possibility, miR-33b–
specific inhibition therapy for atherosclerosis may be a better
treatment strategy for atherosclerosis.
In addition to the increased miR-33b expression levels in
the liver associated with a high-fat and a high-cholesterol diet,
we showed that the abundance of miR-33b was significantly
repressed by cholesterol-decreasing interventions, such as
treatment with a statin and ezetimibe. This is consistent with
the previous observation that SREBF1 expression was
repressed with cholesterol-depletion treatment.33 These data
confirm that the miR-33 expression levels are tightly regulated
by cholesterol burden. Increased expression of miR-33a,
responding to decreased cholesterol burden, is reasonable as
a negative feedback mechanism, to maintain cellular choles-
terol level through the downregulation of ABCA1. However,
enhanced expression of miR-33b in response to increased
cholesterol burden was paradoxical. If this response works as
a positive feedback mechanism, it results in overaccumulation
of cholesterol in cells and could lead to cellular toxicity.
Inconsistent with this hypothesis, we observed increased lipid
content and expression levels of inflammatory genes in the
ApoE/ miR-33 KOKI mice liver in the WTD-fed study.
Figure 9. Continued.
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Systemic inflammation, including steatosis, has been sug-
gested as a contributing factor to atherosclerosis.34,35 Liver
inflammation in the miR-33 KOKI mice also may have
contributed to the increased atherogenicity.
Previously, it was a concern that enhanced expression of
miR-33a during statin treatment, through enhanced Srebf2
expression, resulted in hepatotoxicity.36 However, in the
current study, statin treatment decreased the transcriptional
activity of downstream genes in the LXR signaling, including
Srebf1, and reduced the expression of miR-33b. Because miR-
33b is expressed in the liver at levels 10 times higher than
miR-33a, statin treatment reduced the overall level of miR-33
in the liver. Taking into consideration that the previous
report36 used WT mice with only miR-33a, further evaluation
of the miR-33 family and statin treatment is warranted.
Also, miR-33 WT mice showed significantly increased
HDL-cholesterol levels than miR-33 KOKI mice. There are 2
reports that evaluated the effects on the serum lipid profiles
after pharmacological inhibition of the miR-33 family in
nonhuman primates that carry both miR-33a and miR-
33b.12,13 These reports showed that simultaneous inhibition
of miR-33a and miR-33b increased serum HDL-cholesterol
levels. In the second report,13 the authors focused on the
selective inhibition of miR-33a and miR-33b using selective
anti-miR approaches. However, these selective approaches
failed to increase serum HDL-cholesterol levels or liver ABCA1
expression levels. In this study, we showed distinct effects of
miR-33a and miR-33b on serum HDL-cholesterol levels and the
expression of their target genes. We considered that the
difference between the previous report and ours may be rooted
in the incompleteness of pharmacologic inhibition. In our
results, in the presence of miR-33b, the deletion of miR-33a did
not result in increased serum HDL-cholesterol levels. On the
other hand, miR-33b was highly abundant in the liver, and
Figure 10. Plaque characterization of apolipoprotein E–deficient (ApoE/)/microRNA (miR)-33 wild-
type (WT) or ApoE//miR-33 knock out knock in (KOKI) mice. A, Representative images of
immunostaining for CD68, ATP-binding cassette A (ABCA) 1, and picrosirius red staining. B, Quantification
of positive area (CD68 or ABCA1) or negative area (picrosirius red). For CD68 and ABCA1 staining, n=14 for
WT, and n=10 for KOKI. For picrosirius red staining, n=14 for WT, and n=8 for KOKI. Bar=500 lm.
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complete inhibition of miR-33b could be difficult. Thus, it was
reasonable that only the simultaneous inhibition ofmiR-33a and
miR-33b increased in serumHDL-cholesterol levels and hepatic
ABCA1 expression levels. As support for this discussion, the
authors reported that the absolute copy number of miR-33b is 7
times higher than that of miR-33a in the primate liver.
Contrary to the abbreviating phenotypes on HDL-choles-
terol level, miR-33 KOKI mice in the ApoE/ background
showed a decreased triglyceride level. In the previous report,
we showed decreased triglyceride absorption in miR-33 KI
mice. In this study, the liver phenotype of miR-33 KOKI mice
was similar to that of miR-33 KI mice because of the
abundance of miR-33b. However, in the small intestine, miR-
33a was more abundant compared with miR-33b. From these
data, we assume that the liver miR-33 plays an important role
in the triglyceride absorption; however, to elucidate the
precise roles of the miR-33 family in small intestine, organ-
specific deletion of the miR-33 family is necessary.
Figure 11. Hematopoietic microRNAs (miR-33a and miR-33b) have similar effects on atherosclerotic
plaque formation. A, Representative genotyping polymerase chain reaction analysis of tail and blood cell
genome. B, Representative microscopic images of the proximal aorta in apolipoprotein E–deficient (ApoE/
)/miR-33 wild-type (WT) mice transplanted with bone marrow (BM) obtained from ApoE//miR-33 WT
mice or ApoE//miR-33 knock out knock in (KOKI) mice. Bar=500 lm. C, Quantification of the
atherosclerotic plaque area in cross-sections at the proximal aorta level. D, Serum lipid profiles of ApoE//
miR-33 WT mice transplanted with BM obtained from ApoE//miR-33 WT mice or ApoE//miR-33 KOKI
mice. n=7 for each. Horizontal bars in the dot plots indicate meanSEM. HDLC indicates high-density
lipoprotein-cholesterol; LDLC, low-density lipoprotein-cholesterol; T-Chol, total cholesterol; TG, Triglyceride.
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In addition, in the cholesterol extraction experiments by
mice serum, we found a blunted slope of cholesterol efflux
against serum HDL-cholesterol in the miR-33 KOKI mice
serum compared with the miR-33 WT mice. This suggests that
not only the quantity but also the quality of HDL-cholesterol
was worsened in the miR-33b KOKI mice. Recent studies
emphasize the importance of the quality of HDL-cholesterol
for atherosclerosis progression.6 These factors might con-
tribute to the increased atherogenicity in miR-33 KOKI mice.
Because of the lack of miR-33b in the mice, which is the
most widely used animal model of atherosclerosis, the role of
miR-33b in atherosclerotic plaque formation has not been well
studied. Recently, the role of miR-33b was reported during
atherosclerotic plaque formation in mice.28 However, the
mice used in the this study did not grow to adulthood and
could not be used to assess the whole-body roles of miR-33b
in adult mice. In this study, we used our previously reported
miR-33b KI mice, which showed mendelian segregation and
showed no significant difference in adult body weight with a
normal diet. The data obtained from this strain showed many
consistencies with external data and previous findings. In
particular, the strong correlation between Srebf2/Srebf1 and
miR-33a/b expression patterns was also confirmed in human
primary cultured cell lines. This observation supported the
generalizability of the data obtained from these mice. We
suggest that this strain will also be useful for assessing the
roles of miR-33b in the adult mice, and comparison of the
results with previously reported strains is also important to
understand the biological roles of Srebf1 and miR-33b in vivo.
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Table S1. List of the primers for real-time qPCR assay used in this study. 
 
  
miR-33a sense GGCACTACTTCTGATCCTTC 
miR-33a antisense (WT) CAACTACAATGCACCACAGCTG 
miR-33a antisense (KO) TTGGGATCCAGAATTCGTGATTAA 
miR-33b sense GTACCCACTGGTAGAGCATATC 
miR-33b antisense (WT) CATCACTGAAGCACTGCATCTGC 
miR-33b antisense (KI) AAGTGGATCCAGAATTCGTGA 
Table S2. List of the primers for mice genotyping used in this study. 
 Sense Antisense 
Abca1 AACAGTTTGTGGCCCTTTTG AGTTCCAGGCTGGGGTACTT 
Abcg1 GATTGGGAATGAAGCCAAGA CAGTAGGCCACAGGGAACAT 
Abcg5 AAAACCTTACCCACGGTTCC GTTACTCGCCTCAGCAGGAC 
Abcg8 CCTGATCCGTCGTCAGATTT CCATGGCCGTAGTAAAGGAA 
Actb GATCTGGCACCACACCTTCT GGGGTGTTGAAGGTCTCAAA 
ApoB CTCCAAAGAGGCCAGTCAAG GAGAGGCTTGCAAGTTGACC 
ApoE CAGAGCTCCCAAGTCACACA CCCGTATCTCCTCTGTGCTC 
CCR2 ATCTGCTCAACTTGGCCATC CCCAAAGACCCACTCATTTG 
Cpt1a GATCTACAATTCCCCTCTGCTCT TAGAGCCAGACCTTGAAGTAACG 
Crot TACTTTTACCACGGCCGAAC GACGGTCAAATCCTTTTCCA 
Cyp7a1 GAGCCCTGAAGCAATGAAAG GCTGTCCGGATATTCAAGGA 
F4/80 CCCAGCTTATGCCACCTGCA GGAGCCATTCAAGACAAAGCC 
Fasn GGGTTCTAGCCAGCAGAGTCTA TGAGATGTGGATACCACCAGAG 
Hmgcr CGTAACCCAAAGGGTCAAGA GACCCAAGGAAACCTTAGCC 
Hmgcs2 AGAAATCCCTGGCTCGGGTTG AGCTTTAGACCCCTGAAGGC 
Idol CGAAGCATAAGGAGCTGGAG CCTCACAGCATGCCACTCTA 
IL-10 AAATAAGAGCAAGGCAGTGGAG TCATTCATGGCCTTGTAGACAC 
Il-1β TCAGGCAGGCAGTATCACTCA GGAAGGTCCACGGGAAAGAC 
Il-6 ACCACGGCCTTCCCTACTTC AGATTGTTTTCTGCAAGTGCATCA 
Ldlr ATTGGGTTGATTCCAAACTCC ATTCACATCTGAACCCGTGAG 
Lrp1 CTGAAGGCTCCCGAGTACCAG GTAGGAGATTGTGCCCGTGT 
MCP1 CTGGATCGGAACCAAATGAG TGAGGTGGTTGTGGAAAAGG 
Mvd AAGCAGACGGGCAGTACAGT CCTGGAGGTGTCATTGAGGT 
Pcsk9 TCCATTGGGAAGTGGAAGAC ACCTGCTCTGAAGGACCTGA 
Scd1 GCGATACACTCTGGTGCTCA CCCAGGGAAACCAGGATATT 
Srebf1 TAGAGCATATCCCCCAGGTG GGTACGGGCCACAAGAAGTA 
Srebf2 GTGGAGCAGTCTCAACGTCA TGGTAGGTCTCACCCAGGAG 

















Yellow circles indicate dysregulated metabolites. Predicted miR-33 targets are highlighted in red.  
  
 












Yellow circles indicate dysregulated metabolites. Predicted miR-33 targets are highlighted in red.  





Yellow circles indicate dysregulated metabolites. Predicted miR-33 targets are highlighted in red.  
  
